title: Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers.
abstract: Somnolence and "sleep attacks" have been reported as an adverse effect of several antiparkinsonian drugs. The authors document, in a placebo-controlled, randomized, double-blind, crossover study performed in 20 healthy volunteers, using the Multiple System Latency Test (MSLT) as primary outcome, that ropinirole reduces time to sleep onset in humans. Ropinirole therapy was not associated with daytime episodes of rapid eyes movement (REM) sleep.
authors.affiliation: Egas Moniz Research Center, Lisbon, Portugal.
authors.forename: J J
authors.initials: JJ
authors.lastname: Ferreira
authors.forename: M
authors.initials: M
authors.lastname: Galitzky
authors.forename: C
authors.initials: C
authors.lastname: Thalamas
authors.forename: M
authors.initials: M
authors.lastname: Tiberge
authors.forename: J L
authors.initials: JL
authors.lastname: Montastruc
authors.forename: C
authors.initials: C
authors.lastname: Sampaio
authors.forename: O
authors.initials: O
authors.lastname: Rascol
mesh_terms: D018592:Cross-Over Studies; D006970:Disorders of Excessive Somnolence / Q000139:chemically induced*; D018491:Dopamine Agonists / Q000009:adverse effects*; D004311:Double-Blind Method; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D017448:Receptors, Dopamine D2 / Q000819:agonists; D050637:Receptors, Dopamine D3; D012890:Sleep / Q000187:drug effects*; D012894:Sleep Stages / Q000187:drug effects
chemical_list: C493593:DRD3 protein, human; D018491:Dopamine Agonists; D007211:Indoles; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C046649:ropinirole